GLP-1 Weight Loss Programme (Wegovy / Mounjaro)

FeM Surgery offers medically supervised GLP-1 receptor agonist therapy — the most clinically effective non-surgical weight loss treatment currently available. The programme centres on two HSA-approved medications: semaglutide (Wegovy), a once-weekly injection shown in landmark trials to reduce body weight by an average of 15%, and tirzepatide (Mounjaro), a dual GLP-1 and GIP receptor agonist that has demonstrated up to 22% mean body weight reduction in…

GLP-1 receptor agonists work by mimicking the action of naturally occurring gut hormones that regulate appetite and blood glucose. They slow gastric emptying, reduce hunger signals in the brain, and improve insulin sensitivity — resulting in reduced caloric intake and meaningful weight loss without requiring surgical intervention.

The programme at FeM Surgery begins with a thorough clinical consultation to confirm patient suitability for GLP-1 therapy. Contraindications are carefully screened, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, and severe gastrointestinal disease. Baseline blood tests are completed to establish metabolic status before therapy begins.